With 33 outbound* projects and 26 inbound* projects, CNR Research has successfully conducted numerous multinational clinical trials, demonstrating its exceptional ability to respond flexibly to complex country-specific regulations and diverse clinical environments. All processes are supported by strict standard operating procedures (SOPs) and a systematic quality management system to ensure high-quality clinical results.

With over 20 years of RA (regulatory affairs) experience, our team of experts is well-versed in the rigorous approval processes of major global regulatory agencies such as the US FDA and European EMA. From pre-IND clinical trial protocols to IND submissions, IB, CTD, and IMPD documentation, as well as orphan drug designation (ODD) applications, the expertise we have accumulated through close collaboration with global regulatory agencies is a unique strength that enables us to provide stable and efficient regulatory support to our clients.

CNR Research provides organic and integrated services throughout the entire new drug development cycle through close collaboration with its subsidiaries and multinational affiliates. Rapid patient recruitment is possible thanks to quick patient access utilizing Korea's excellent clinical infrastructure, and clinical data is processed accurately and efficiently through thorough data management and biostatistical capabilities.
Additionally, through a team of medical professionals led by Medical Doctors within the clinical development department, we offer comprehensive medical writing and regulatory services, including medical consulting and the preparation of clinical study reports (CSRs), across the entire development cycle. This enables us to deliver accurate, efficient, and high-quality clinical results that global sponsors can trust, thereby enhancing satisfaction.